Home Ingredients Red Yeast Rice (Monascus purpureus)
Cardiovascular

Red Yeast Rice (Monascus purpureus)

Monascus purpureus
Evidence Level
Strong
2 Clinical Trials
5 Documented Benefits
4/5 Evidence Score

Red yeast rice (RYR) is rice fermented with Monascus purpureus yeast — produces monacolin K, which is bioidentical to lovastatin (Mevacor®, prescription statin). Used in traditional Chinese medicine and modern statin-alternative supplements. Critical regulatory issue: FDA has determined products containing more than trace monacolin K are unapproved drugs; quality and dosing vary enormously. Genuinely effective for cholesterol but carries same statin risks (myopathy, liver) plus potential citrinin contamination.

Studied Dose 1,200-2,400 mg/day red yeast rice extract; clinically effective dose typically provides 5-10 mg monacolin K/day (similar to low-dose lovastatin)
Active Compound Monacolin K (lovastatin) plus other monacolins from Monascus fermentation

Benefits

Effective LDL Cholesterol Reduction

Red yeast rice (when adequately dosed with monacolin K) reduces LDL cholesterol 15-25% — comparable to low-dose statins. A trial in statin-intolerant patients showed RYR + lifestyle modestly more effective than placebo + lifestyle. Multiple meta-analyses confirm efficacy.

Supported by Trial 1

Statin Alternative for Statin-Intolerant Patients

Some patients who cannot tolerate prescription statins (myalgia) report better tolerance of red yeast rice — possibly due to lower monacolin K dose or other Monascus compounds. A trial supports this approach. Clinical alternative when statins not tolerated.

Supported by Trial 1

Cardiovascular Outcomes (Limited)

The China Coronary Secondary Prevention Study (Lu 2008, PMID 18549841) tested Xuezhikang, a specific standardized pharmaceutical red yeast rice extract and not a generic supplement, in about 4,870 Chinese patients who had already had a heart attack. Over an average of 4.5 years, major coronary events fell from 10.4% on placebo to 5.7% (a 45% relative reduction) and total mortality was about 33% lower. This is a secondary-prevention result in an established coronary-disease population using one standardized product. It does not show that a generic red yeast rice supplement prevents heart attacks or death, and consumer products vary too much in potency to assume the same effect.

Supported by Trial 2

Multi-Component Synergy

Beyond monacolin K, RYR contains other monacolins, plant sterols, isoflavones, monounsaturated fatty acids — potentially synergistic effects beyond just statin-equivalent activity.

Lower Cost than Some Statins

Generic statins (lovastatin, simvastatin, atorvastatin) are now extremely cheap; RYR cost advantage over generics is minimal. Cost relevant only vs branded statins.

Mechanism of action

1

HMG-CoA Reductase Inhibition (Same as Statins)

Monacolin K is bioidentical to lovastatin — same chemical structure, same mechanism. Inhibits HMG-CoA reductase (rate-limiting enzyme in cholesterol synthesis) — reducing hepatic cholesterol production and upregulating LDL receptors.

2

Other Monacolins

Monascus produces multiple monacolin compounds beyond K — may have additive HMG-CoA reductase inhibition or other effects. Total 'monacolin' content varies by product and fermentation conditions.

3

Variable Standardization

RYR products vary 100-fold in monacolin K content — from <0.1 mg to 10+ mg per serving. FDA crackdowns have caused some manufacturers to deliberately reduce monacolin K to avoid 'unapproved drug' status; these products may be ineffective.

4

Citrinin Contamination Risk

Monascus fermentation can produce citrinin — a nephrotoxic mycotoxin. Quality manufacturers test for citrinin; cheap unstandardized products may have detectable levels. Important quality consideration.

Clinical trials

1
Red Yeast Rice for Statin-Intolerant Patients
PubMed

Clinical trial of red yeast rice vs placebo in statin-intolerant hyperlipidemic patients for 24 weeks.

Statin-intolerant patients.

RYR significantly reduced LDL vs placebo with comparable tolerability. Established RYR as reasonable option for statin-intolerant patients. Subsequent trials supportive.

2
China Coronary Secondary Prevention Study
PubMed

Large clinical trial (n=4,870) of Xuezhikang (Chinese RYR product) vs placebo in patients with prior MI for 4 years.

4,870 post-MI Chinese patients.

Xuezhikang reduced major CV events by ~45% and total mortality by ~33% vs placebo. Critical caveat: Xuezhikang is standardized; consumer RYR products vary widely; results may not translate to all RYR products.

Side effects and drug interactions

Common Potential side effects

Muscle pain / myalgia — same statin class effect; can progress to severe myopathy or rhabdomyolysis at high doses or with drug interactions; same risk as lovastatin.
Liver enzyme elevation — same statin class effect; periodic LFT monitoring appropriate.
GI distress (nausea, heartburn, gas).
Headache.
CoQ10 depletion — same statin pathway; supplementation often paired.
Citrinin nephrotoxicity (in poorly-manufactured products).
Allergic reactions to Monascus rare.

Important Drug interactions

Statins — additive effects; do not combine with prescription statins.
Fibrates (gemfibrozil, fenofibrate) — increased rhabdomyolysis risk.
Grapefruit juice — inhibits CYP3A4 metabolism of monacolin K (same as lovastatin); avoid concurrent use.
Macrolide antibiotics (erythromycin, clarithromycin) — CYP3A4 inhibitors; increased monacolin K levels.
Azole antifungals (ketoconazole, itraconazole) — CYP3A4 inhibitors; increased monacolin K levels.
HIV protease inhibitors — CYP3A4 inhibitors.
Cyclosporine — increased rhabdomyolysis risk.
Niacin (high-dose) — additive lipid effects but increased myopathy risk.
Warfarin — RYR may modestly enhance anticoagulation; monitor INR.
CoQ10 — supplementation often recommended (same rationale as with statins).

Featured in these supplement guides

High Cholesterol→

More Cardiovascular Ingredients

Cardiovascular
Potassium
Potassium is the most abundant intracellular cation in the human body and an essential min…
Cardiovascular
CoroWise® (Plant Sterols for Cholesterol — Cargill)
CoroWise is Cargill's brand of plant sterols (phytosterols), which carry an FDA-authorized…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cardiovascular
CoEnzyme Q10
Coenzyme Q10 (CoQ10) is a lipid-soluble compound essential to mitochondrial ATP production…

Explore Other Ingredients

Metabolic Health
Magnesium
Magnesium is the fourth most abundant mineral in the body and a cofactor for over 300 enzy…
Cardiovascular
Beetroot
Beetroot is a vegetable rich in dietary nitrate, which the body converts into nitric oxide…
Athletic Performance
L-Carnitine
L-Carnitine is a naturally-occurring amino acid derivative essential for fatty acid metabo…

Related articles from our blog

📝 Article
The 5 Best Red Yeast Rice Supplements for Heart & Cholesterol Health in 2026
Disclosure: NutraSmarts is reader-supported. Links marked affiliate link below may earn us a commission if you buy throu…
June 28, 2025
📝 Article
Red Yeast Rice and Nattokinase for Cholesterol: A 1,110-Person 2026 Trial
A large new trial gave the "natural cholesterol" crowd a genuine talking point: a supplement combining red yeast rice wi…
📝 Article
💓 Understanding Blood Pressure and Supplements That Can Help
Blood pressure is a vital measure of your cardiovascular health, indicating the force of blood pushing against the walls…
June 06, 2025

Frequently asked questions about Red Yeast Rice (Monascus purpureus)

What is red yeast rice used for?

Red yeast rice is a traditional fermented rice product used to support healthy cholesterol. It naturally contains monacolin K, which is chemically identical to the statin drug lovastatin, which is why it can lower LDL cholesterol.

Is red yeast rice like a statin?

Yes, in effect. Its active compound monacolin K is the same molecule as the prescription statin lovastatin, so effective products work like a low-dose statin and carry similar considerations and side effects. Potency varies widely between products, which is a real concern.

How much red yeast rice should I take?

Studies have used about 1,200 to 2,400 mg per day, but monacolin content varies enormously and is often not labeled. Because of this inconsistency and its statin-like nature, it should be used under medical guidance.

Is red yeast rice safe?

Because it acts like a statin, it can cause the same side effects (muscle aches, liver effects) and interactions, and some products contain a harmful contaminant (citrinin) or unpredictable potency. Do not combine it with statins, and use it only with your doctor's knowledge and monitoring.

What is Red Yeast Rice?

Red yeast rice (RYR) is rice fermented with Monascus purpureus yeast — produces monacolin K, which is bioidentical to lovastatin (Mevacor®, prescription statin). Used in traditional Chinese medicine and modern statin-alternative supplements.

What is the recommended dosage of Red Yeast Rice?

The clinically studied dose is 1,200-2,400 mg/day red yeast rice extract; clinically effective dose typically provides 5-10 mg monacolin K/day (similar to low-dose lovastatin) Always follow the product label and check with a healthcare provider for personal advice.

Is Red Yeast Rice safe, and does it have side effects?

For most healthy adults, Red Yeast Rice is well tolerated at studied doses. Reported effects can include: Muscle pain / myalgia — same statin class effect; can progress to severe myopathy or rhabdomyolysis at high doses or with drug interactions; same risk as lovastatin. Liver enzyme elevation — same statin class effect; periodic LFT monitoring appropriate. It may also interact with some medications. Red Yeast Rice is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Red Yeast Rice interact with any medications?

Possible interactions include: Statins — additive effects; do not combine with prescription statins. Fibrates (gemfibrozil, fenofibrate) — increased rhabdomyolysis risk. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Red Yeast Rice?

NutraSmarts rates the evidence for Red Yeast Rice as Strong (4 out of 5). It is backed by 2 clinical trials and 5 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(5 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150(12):830-9, W147-9. doi: 10.7326/0003-4819-150-12-200906160-00006.PubMedUsed to support: Landmark LDL RCT supporting the cholesterol-lowering claim: in 62 statin-intolerant patients, red yeast rice plus therapeutic lifestyle change significantly lowered LDL cholesterol versus placebo over 24 weeks without raising creatine kinase or pain. The LDL lowering reflects the product's monacolin K content, which is chemically identical to the statin lovastatin.
  2. Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. Atherosclerosis. 2015;240(2):415-23. doi: 10.1016/j.atherosclerosis.2015.04.004.PubMedUsed to support: Meta-analysis (20 studies) quantifying the lipid effect: red yeast rice lowered LDL cholesterol by about 1.02 mmol/L (about 39 mg/dL), comparable to moderate-intensity statins such as pravastatin 40 mg or lovastatin 20 mg. Honest caveat: the authors judged safety assessment to be inadequate in most trials, so long-term safety is uncertain.
  3. Li Y, Jiang L, Jia Z, Xin W, Yang S, Yang Q, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One. 2014;9(6):e98611. doi: 10.1371/journal.pone.0098611.PubMedUsed to support: Supporting meta-analysis (13 placebo-controlled RCTs, 804 participants): red yeast rice significantly lowered total cholesterol, LDL cholesterol and triglycerides with no serious adverse effects reported. Authors note further long-term rigorous trials are needed before recommending it as a statin alternative.
  4. Cohen PA, Avula B, Khan IA. Variability in strength of red yeast rice supplements purchased from mainstream retailers. Eur J Prev Cardiol. 2017;24(13):1431-1434. doi: 10.1177/2047487317715714.PubMedUsed to support: Safety/quality caveat for the potency-variability claim: analysis of 28 commercial brands found monacolin K absent in 2 brands and ranging more than 60-fold (0.09 to 5.48 mg per 1200 mg) among the rest, and detected the nephrotoxic contaminant citrinin in some products. Dose (and therefore both efficacy and statin-like risk) is unpredictable between brands.
  5. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM, Li S; Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101(12):1689-93. doi: 10.1016/j.amjcard.2008.02.056.PubMedUsed to support: Secondary-prevention outcome trial of Xuezhikang, a specific standardized pharmaceutical red yeast rice extract and not a generic supplement, in about 4,870 Chinese patients who had already had a myocardial infarction. Over an average of 4.5 years, major coronary events fell from 10.4% on placebo to 5.7% (a 45% relative reduction), total mortality was about 33% lower, and cardiovascular mortality about 30% lower. The result applies to this one standardized product in an established coronary-disease population and does not establish that variable-potency consumer red yeast rice prevents heart attacks or death.